151. Rasmussen encephalitis
2 clinical trials,   4 drugs   (DrugBank: 2 drugs),   6 drug target genes,   84 drug target pathways

Searched query = "Rasmussen encephalitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04003922
(ClinicalTrials.gov)
October 1, 201920/6/2019Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long TermObservational Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long TermRasmussen EncephalitisOther: Adalimumab treatmentAssistance Publique Hopitaux De MarseilleNULLNot yet recruiting2 YearsN/AAll40NULL
2NCT00545493
(ClinicalTrials.gov)
November 200216/10/2007Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen EncephalitisEfficacy of Tacrolimus and i.v.-Immunoglobulins in Rasmussen Encephalitis With Start of Treatment in the Acute Disease Stage. Prospective, Randomised, Open Parallel Group StudyRasmussen EncephalitisDrug: Tacrolimus;Drug: i.v. immunoglobulinsUniversity Hospital, BonnOctapharma;Astellas Pharma GmbHActive, not recruitingN/AN/ABoth16Phase 2;Phase 3Germany